News

FDA appoints Public Private Partnership Liaison to ARC
To focus on the challenges faced by AL amyloidosis, a particularly complex and multi-systemic disease, and bridge the gaps in drug discovery and development . (more…)
Read More
Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) approved by FDA for ATTR amyloidosis cardiomyopathy
This represents the first FDA approved treatment in ATTR-CM for both the wild-type and hereditary forms of ATTR amyloidosis. (more…)
Read More
Patient Perspectives from the FDA Public Meeting: the Impact of Rare Diseases
I recently had the opportunity to attend this public meeting at the FDA to discuss the Patient Perspectives on the Impact of Rare Diseases. This meeting was held as opportunity to bring the voices of patients and caregivers to the...
Read More
Advancing Amyloidosis: Roadmap for Research
FOR IMMEDIATE RELEASE LEADING EXPERTS PUBLISH A ROADMAP FOR CRITICAL AREAS OF RESEARCH IN AMYLOIDOSIS (more…)
Read More
ARC’s Advocates work Capitol Hill
Our ARC team of amyloidosis patients, caregivers and ARC staff took part as advocates in key activities during the week of Rare Disease Day, which is held on February 28th each year.  (more…)
Read More

AMYLOIDOSIS RESEARCH CONSORTIUM, INC.
320 Nevada Street, Suite 210 Newton, MA 02460 USA | 617-467-5170
arc@arci.org

ARC is a 501(c)(3) nonprofit organization